Drug intelligence / Profile preview

albendazole + secnidazole

Development stage
Preclinical
Lead developer
GSK
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Albendazole + secnidazole is a combination of two small-molecule antiparasitic and antimicrobial agents. Albendazole is a benzimidazole anthelmintic that inhibits microtubule polymerization by binding to β-tubulin in susceptible parasites, leading to impaired glucose uptake and depletion of energy stores, ultimately causing parasite death[6][8][10]. Secnidazole is a nitroimidazole antimicrobial that exerts its effect by reduction of its nitro group within anaerobic organisms, generating reactive intermediates that damage DNA and other critical biomolecules, resulting in cell death[4][9]. This combination has been used as an alternative therapy for refractory giardiasis (Giardia lamblia infection), particularly in pediatric patients who have failed conventional treatments. The regimen has demonstrated efficacy with good tolerability in small clinical series[2][5].

02

Targets

TUBB (Tubulin (alpha and beta subunits))CYP2C19 (Cytochrome P450 2C19)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on albendazole + secnidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on albendazole + secnidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call